{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:23:06Z","timestamp":1782962586198,"version":"3.54.5"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jmoldx.2019.04.011","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T12:47:46Z","timestamp":1561639666000},"page":"796-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin\u2013Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform"],"prefix":"10.1016","volume":"21","author":[{"given":"Zhenhao","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Cogswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid P.","family":"Kerkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Vitazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2019.04.011_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1389450116666141210094640","article-title":"Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine","volume":"16","author":"Coco","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib3","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/modpathol.2011.153","article-title":"Utility of small biopsies for diagnosis of lung nodules: doing more with less","volume":"25 Suppl 1","author":"Mukhopadhyay","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.5858\/arpa.2012-0263-RA","article-title":"Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society classification","volume":"137","author":"Travis","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fonc.2014.00204","article-title":"Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS","volume":"4","author":"Korpanty","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.21037\/tlcr.2017.05.09","article-title":"Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology","volume":"6","author":"Gridelli","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12967-017-1325-2","article-title":"The need for a network to establish and validate predictive biomarkers in cancer immunotherapy","volume":"15","author":"Masucci","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib10","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/j.jtho.2016.11.322","article-title":"Willingness for multiple biopsies to improve quality of lung cancer care: understanding the patient perspective","volume":"12","author":"Roy","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-155-3-201108020-00003","article-title":"Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records","volume":"155","author":"Wiener","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib12","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.3747\/co.19.1062","article-title":"The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment","volume":"19","author":"Ofiara","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib13","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib15","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/humu.22014","article-title":"A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding","volume":"33","author":"Wang","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib20","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1158\/1078-0432.CCR-15-2900","article-title":"An expression signature as an aid to the histologic classification of non\u2013small cell lung cancer","volume":"22","author":"Girard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib21","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib23","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2015.66.0084","article-title":"The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non\u2013small-cell lung cancer","volume":"34","author":"Papadimitrakopoulou","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2009.09.013","article-title":"Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy","volume":"69","author":"Li","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3036","article-title":"Relationship of baseline tumoral IFN\u03b3 mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients","volume":"34","author":"Higgs","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib27","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1940-6207.CAPR-11-0441","article-title":"The state of molecular biomarkers for the early detection of lung cancer","volume":"5","author":"Hassanein","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib28","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.5858\/arpa.2016-0156-RA","article-title":"Do more with less: tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing: the University of Colorado experience","volume":"140","author":"Aisner","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib29","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/path.2728","article-title":"Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay","volume":"221","author":"Waddell","year":"2010","journal-title":"J Pathol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nrg1473","article-title":"The social and ethical issues of post-genomic human biobanks","volume":"5","author":"Cambon-Thomsen","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrclinonc.2011.114","article-title":"The ethical use of mandatory research biopsies","volume":"8","author":"Olson","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib33","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1016\/j.jtho.2016.08.112","article-title":"P2.41 (also presented as PD1.06): pembrolizumab vs docetaxel for previously treated NSCLC (KEYNOTE-010): archival vs new tumor samples for PD-L1 assessment: track: immunotherapy","volume":"11","author":"Herbst","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3025","article-title":"PD-L1 expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age","volume":"34","author":"Midha","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib35","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4155\/bio-2016-0186","article-title":"Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples","volume":"8","author":"Qi","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib36","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1016\/j.jtho.2016.11.785","article-title":"Creation and early validation of prognostic miRNA signatures for squamous cell lung carcinoma by the SPECS Lung Consortium","volume":"12","author":"Harpole","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib37","series-title":"50 tests for use with Autostainer Link 48. Silver Spring, MD: U.S. Food & Drug Administration","year":"2015"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1538-7445.AM2016-1383","article-title":"Abstract 1383: NGS-based measurement of gene expression of 2560 oncology-related biomarkers in formalin-fixed, paraffin-embedded (FFPE) tissues","volume":"76","author":"Reinholz","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib41","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1471-2105-11-367","article-title":"A flexible R package for nonnegative matrix factorization","volume":"11","author":"Gaujoux","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib44","first-page":"91","article-title":"Preliminary efficacy from a phase I\/II study of the natural killer cell\u2013targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck","volume":"4","author":"Leidner","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/thoraxjnl-2014-206677","article-title":"Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group","volume":"71","author":"Dietel","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib46","doi-asserted-by":"crossref","first-page":"e56333","DOI":"10.1371\/journal.pone.0056333","article-title":"Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples","volume":"8","author":"Kayser","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib47","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib48","doi-asserted-by":"crossref","first-page":"9837310","DOI":"10.1155\/2016\/9837310","article-title":"RNA sequencing of formalin-fixed, paraffin-embedded specimens for gene expression quantification and data mining","volume":"2016","author":"Guo","year":"2016","journal-title":"Int J Genomics"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1472-6750-11-46","article-title":"mRNA transcript quantification in archival samples using multiplexed, color-coded probes","volume":"11","author":"Reis","year":"2011","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib50","doi-asserted-by":"crossref","first-page":"e1261","DOI":"10.1371\/journal.pone.0001261","article-title":"Determinants of RNA quality from FFPE samples","volume":"2","author":"von Ahlfen","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib51","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0002-9440(10)64472-0","article-title":"Effect of fixatives and tissue processing on the content and integrity of nucleic acids","volume":"161","author":"Srinivasan","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib52","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2018.36.6_suppl.511","article-title":"Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC)","volume":"36 6_suppl","author":"Galsky","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib53","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2018.36.15_suppl.4546","article-title":"Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC)","volume":"36 15_suppl","author":"Koshkin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib54","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/1538-7445.AM2018-4054","article-title":"Abstract 4054: gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC)","volume":"78 Suppl","author":"Tang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib55","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.2016.34.15_suppl.3592","article-title":"Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC)","volume":"34 15_suppl","author":"Sunakawa","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib56","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1200\/JCO.2016.34.15_suppl.11559","article-title":"Next generation sequencing for DLBCL classification","volume":"34 15_suppl","author":"Reinholz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib57","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1200\/JCO.2017.35.15_suppl.11613","article-title":"Association of immune-related genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for metastatic colorectal cancer (mCRC): JACCRO CC-05\/06AR","volume":"35 15_suppl","author":"Sunakawa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib58","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers7030859","article-title":"Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies","volume":"7","author":"Chen","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2220\/biomedres.37.233","article-title":"Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling: Project HOPE","volume":"37","author":"Akiyama","year":"2016","journal-title":"Biomed Res"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib60","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib61","doi-asserted-by":"crossref","first-page":"e17163","DOI":"10.1371\/journal.pone.0017163","article-title":"Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue","volume":"6","author":"Mittempergher","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semradonc.2007.10.006","article-title":"Tissue microarrays in clinical oncology","volume":"18","author":"Voduc","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jmoldx.2019.04.011_bib63","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1158\/1078-0432.CCR-15-2889","article-title":"Intratumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer","volume":"22","author":"Gyanchandani","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157818303805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157818303805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:13:22Z","timestamp":1761502402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157818303805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1525157818303805"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.04.011","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin\u2013Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}